Released Mar 5, 2024, after the close
10-K filed Mar 5, 2024, 65 days after period end · 0000950170-24-025877
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$200.42M$200.42M derived+64.0% vs Q4 2022+8.9% vs Q3 2023
Net Income-$22.17M-$22.17M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$136,630,000+53.2%
Operating Incomederived-$18,315,000N/M
Operating Cash Flowderived-$6,694,000N/M
Free Cash Flowderived-$21,255,000N/M
Margins · derived
Gross margin68.2%−4.8 pt vs Q4 2022
Operating margin-9.1%−0.1 pt vs Q4 2022
Net margin-11.1%−5.3 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $200.42M | $122.23M | $125.06M | $117.62M |
| Net Income | -$22.17M | -$7.06M | -$32.81M | -$9.38M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR